Phase II study of intrathecal administration of trastuzumab in patients with HER2-positive breast cancer with leptomeningeal metastasis.
HER2-positive breast cancer
intrathecal treatment
leptomeningeal carcinomatosis
trastuzumab
Journal
Neuro-oncology
ISSN: 1523-5866
Titre abrégé: Neuro Oncol
Pays: England
ID NLM: 100887420
Informations de publication
Date de publication:
14 02 2023
14 02 2023
Historique:
pubmed:
23
7
2022
medline:
16
2
2023
entrez:
22
7
2022
Statut:
ppublish
Résumé
Patients with HER2-positive breast cancer (HER2 + BC) develop central nervous system metastases twice as often as patients with luminal HER2-negative breast cancer. Leptomeningeal progression results in a drastically altered prognosis with limited therapeutic options. This phase II study was conducted to assess the efficacy of intrathecal (IT) trastuzumab in HER2 + BC patients with leptomeningeal metastasis (LM), based on a phase I dose-escalation study that had determined the recommended weekly dose of 150 mg for phase II. Eligible patients received weekly administrations of 150 mg of IT trastuzumab. The primary endpoint was clinical neurologic progression-free survival (LM-related-PFS) after 8 weeks. Overall survival (OS), toxicities, and quality of life (QoL) were secondary endpoints. Among the 19 enrolled patients, 16 (84%) had concomitant brain metastases, 15 of them had received prior radiotherapy to the brain. All patients had received at least one line of systemic anti-HER2 therapy. After 8 weeks, 14 patients (74%) were free of neurological progression. The median LM-related-PFS was 5.9 months and the median OS was 7.9 months. According to the QLQ-C30 and BN20 scales, the global health-related QoL status seemed preserved and no toxicity above grade 3 was observed. Conducting studies on patients with LM poses significant challenges and ethical dilemmas inherent to this population. Despite some limits, this phase II study's findings in terms of clinical neurologic response and QoL's control confirms weekly administration of 150 mg of IT trastuzumab as a valuable option for HER + BC patients with LM and support the interest for further investigations.
Sections du résumé
BACKGROUND
Patients with HER2-positive breast cancer (HER2 + BC) develop central nervous system metastases twice as often as patients with luminal HER2-negative breast cancer. Leptomeningeal progression results in a drastically altered prognosis with limited therapeutic options. This phase II study was conducted to assess the efficacy of intrathecal (IT) trastuzumab in HER2 + BC patients with leptomeningeal metastasis (LM), based on a phase I dose-escalation study that had determined the recommended weekly dose of 150 mg for phase II.
METHODS
Eligible patients received weekly administrations of 150 mg of IT trastuzumab. The primary endpoint was clinical neurologic progression-free survival (LM-related-PFS) after 8 weeks. Overall survival (OS), toxicities, and quality of life (QoL) were secondary endpoints.
RESULTS
Among the 19 enrolled patients, 16 (84%) had concomitant brain metastases, 15 of them had received prior radiotherapy to the brain. All patients had received at least one line of systemic anti-HER2 therapy. After 8 weeks, 14 patients (74%) were free of neurological progression. The median LM-related-PFS was 5.9 months and the median OS was 7.9 months. According to the QLQ-C30 and BN20 scales, the global health-related QoL status seemed preserved and no toxicity above grade 3 was observed.
CONCLUSIONS
Conducting studies on patients with LM poses significant challenges and ethical dilemmas inherent to this population. Despite some limits, this phase II study's findings in terms of clinical neurologic response and QoL's control confirms weekly administration of 150 mg of IT trastuzumab as a valuable option for HER + BC patients with LM and support the interest for further investigations.
Identifiants
pubmed: 35868630
pii: 6648801
doi: 10.1093/neuonc/noac180
pmc: PMC9925703
doi:
Substances chimiques
Trastuzumab
P188ANX8CK
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Clinical Trial, Phase II
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
365-374Commentaires et corrections
Type : CommentIn
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
N Engl J Med. 2020 Feb 13;382(7):610-621
pubmed: 31825192
J Biomed Biotechnol. 2011;2011:379123
pubmed: 21660134
Oncotarget. 2016 Jan 26;7(4):3740-7
pubmed: 26543235
Clin Pharmacol Ther. 2021 Jul;110(1):210-219
pubmed: 33547646
Ann Oncol. 2005 Nov;16(11):1772-7
pubmed: 16150805
Eur J Cancer. 2002 Mar;38 Suppl 4:S125-33
pubmed: 11858978
Cancer. 2010 Apr 15;116(8):1947-52
pubmed: 20151421
Ann Oncol. 2017 Jul 1;28(suppl_4):iv84-iv99
pubmed: 28881917
Eur J Cancer. 2012 Jul;48(11):1713-21
pubmed: 22418017
J Clin Oncol. 2020 Sep 20;38(27):3138-3149
pubmed: 32678716
Eur J Cancer. 2018 May;95:75-84
pubmed: 29635147
Eur J Cancer. 2020 Jan;125:22-30
pubmed: 31835235
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
Neuro Oncol. 2020 Apr 15;22(4):524-538
pubmed: 31637444
J Clin Oncol. 2008 Apr 10;26(11):1789-96
pubmed: 18347005
Neuro Oncol. 2021 Jul 1;23(7):1100-1112
pubmed: 33367859
J Clin Oncol. 2020 Aug 10;38(23):2610-2619
pubmed: 32468955
Neuro Oncol. 2017 Apr 1;19(4):484-492
pubmed: 28039364
N Engl J Med. 1975 Jul 24;293(4):161-6
pubmed: 806016
J Clin Oncol. 2010 Jul 10;28(20):3271-7
pubmed: 20498394
Cancer Treat Rev. 2020 Aug;88:102046
pubmed: 32599393
Anticancer Drugs. 2007 Jan;18(1):23-8
pubmed: 17159499
J Neurooncol. 2007 Aug;84(1):57-62
pubmed: 17310266
Neuro Oncol. 2019 May 6;21(5):648-658
pubmed: 30715514
J Clin Oncol. 2004 Jul 15;22(14):2865-72
pubmed: 15254054
Eur J Cancer. 2020 Apr;129:60-70
pubmed: 32135312
N Engl J Med. 2020 Feb 13;382(7):597-609
pubmed: 31825569
JAMA Oncol. 2017 Mar 01;3(3):335-341
pubmed: 27812689
N Engl J Med. 2001 Mar 15;344(11):783-92
pubmed: 11248153
J Hematol Oncol. 2013 Jan 04;6:1
pubmed: 23286345
Ann Oncol. 2011 Sep;22(9):2107-2112
pubmed: 21324954